ABSTRACT
Introduction Early-onset neonatal infection (EONI) poses significant risks to neonatal health, necessitating reliable diagnostic markers for early detection. This study aims to evaluate the diagnostic validity of procalcitonin (PCT) concentration in umbilical cord blood as a biomarker for EONI.
Methods This prospective study was conducted at Ho Chi Minh University Medical Center from April 2022 to September 2022. One hundred eighty neonates with risk factors for EONI were recruited. The PCT level was measured in umbilical cord blood at birth. Based on clinical, laboratory, and microbiologic results, neonates were classified into infected and non-infected groups.
Results Among the neonates studied, 22 (12.2%) were classified as infected and 158 (87.8%) as non-infected. The median PCT in the infected group was significantly higher than that in the non-infected group (0.389 ng/mL vs 0.127 ng/mL, p = 0.007). The optimal PCT cut-off was found by Receiver Operating Characteristic (ROC) to be 0.23 ng/mL, with an area under the curve of 0.87. The results were 59.1%, 98.7%, 86.2%, 94%, 45, and 0.41 for sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, respectively. The post-test probability was 86% if the test was positive and 5% if it was negative.
Conclusion Umbilical cord blood PCT is a reliable marker in the diagnosis of EONI, and its value helps limit the harmful effects of unnecessary prescriptions in non-infected neonates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no financial support for the research, authorship, and publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethical approval from the Institutional Review Board (IRB) of Ho Chi Minh University Medical Center on June 14th, 2022 (Project No.: 2022/46).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data contained within this article is not available due to privacy issues.
